Current Topics in Oncology

Download All
Experts discuss key topics in contemporary cancer treatment in this podcast series that includes downloadable summary slidesets.
person default
Jean Yves Blay, MD, PhD
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Josep M. Llovet, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA

TKIs in Solid Tumors

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss key data on using TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 2, 2021

Download this summary slideset to accompany a podcast featuring expert discussion on key clinical trial data on leveraging TKIs as single agents or in combination with cytotoxics or immune checkpoint inhibitors for treatment of soft tissue sarcomas and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 3, 2021

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

Summary slides for a podcast where Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings